PITX2 Methylation Biomarker Test Validated on Prostate Cancer Tissue Biopsies | GenomeWeb

NEW YORK (GenomeWeb) – Researchers in Germany have found that a PCR-based method to detect methylation of a biomarker gene found in biopsy samples could anticipate prostate cancer recurrence and be used to prevent unneeded radical treatments. 

The assay detects methylation of the PITX2 gene, and was shown to discriminate between cancer and non-cancerous tissue as well as to predict biochemical recurrence after surgery. Importantly, the researchers also found the assay was sensitive enough that it could yield results even with small core needle biopsy samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.